Senex Biotechnology Inc.

Maynard, MA

UEI
G8XKMW3DYMQ6
CAGE
47JH9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
10 Digital Wy, Maynard, MA 01754, USA
Website
senexbio.com
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Nanoparticle formulation of mediator kinase inhibitor for the treatment of peritoneal ovarian cancer - metastatic… R41CA298223 National Cancer Institute (NIH) $800,000
Preventing in vivo resistance to PI3K/AKT/mtor inhibitors through mediator kinase inhibition - dysregulation of the… R43CA271996 National Cancer Institute (NIH) $800,000
Developing mediator kinase inhibitor for castration-refractory prostate cancer W81XWH2210205 Defense Health Agency $1,050,000
Targeting CDK8 for the treatment of vein graft failure R43HL137525 National Heart Lung and Blood Institute (NIH) $299,151
CDK8/19 inhibitor for the treatment of HER2+ breast cancer R43CA221485 National Cancer Institute (NIH) $299,993

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Creative Biotherapeutics LLC UEI YNJ8ST14PBD8 Gurnee, IL —
Athna Biotech Inc. UEI LBCCTS71U2N4 Watkinsville, GA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PDX Pharmaceuticals Inc. UEI VTX7JRKLC3F5 Portland, OR 541713 Research and Development in Nanotechnology
Viewpoint Molecular Targeting, Inc. UEI RDZCK3F6AU73 Coralville, IA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Window Therapeutics, Inc. UEI JFLXDJ3ZY975 Boston, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Senex Biotechnology Inc. is a for-profit corporate entity registered in SAM.gov since November 2005, specializing in advanced biotechnology research and drug development focused on cancer therapeutics. The company appears to be a research-driven organization that develops innovative pharmaceutical interventions, particularly targeting complex cancer treatments through novel molecular approaches. Its primary focus seems to be on developing specialized drug formulations and inhibitor technologies that address challenging aspects of cancer treatment, with a particular emphasis on creating targeted therapies for hard-to-treat cancer subtypes.

The company has secured multiple significant federal grant awards from both civilian and defense agencies, primarily the National Cancer Institute and Defense Health Agency, totaling approximately $800,000 in research funding. These grants have supported sophisticated research projects in cancer treatment, including developing nanoparticle formulations for ovarian cancer metastases, investigating mechanisms to prevent drug resistance in PI3K/AKT/MTOR inhibitor treatments, and exploring mediator kinase inhibitors for castration-refractory prostate cancer. The grants, which are structured as Project Grants, demonstrate Senex Biotechnology's advanced scientific capabilities in creating innovative drug delivery mechanisms and exploring complex molecular interventions. Specifically, their research has involved developing stable nanoparticle formulations, analyzing pharmacokinetics, evaluating tumor suppression mechanisms, and conducting transcriptomic analyses to identify potential treatment markers across different cancer subtypes.

Quick answers

Is Senex Biotechnology Inc. registered in SAM.gov?

Yes. Senex Biotechnology Inc.'s SAM.gov registration is active through August 27, 2027.

What is Senex Biotechnology Inc.'s CAGE code?

Senex Biotechnology Inc.'s CAGE code is 47JH9, and its Unique Entity ID (UEI) is G8XKMW3DYMQ6.

What is Senex Biotechnology Inc.'s most recent federal award?

Senex Biotechnology Inc.'s most recent federal grant award is Nanoparticle formulation of mediator kinase inhibitor for the treatment of peritoneal ovarian cancer - metastatic… (R41CA298223), from National Cancer Institute (NIH), on December 13, 2024.

On GovTribe

See Senex Biotechnology Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe